Ixazomib citrate (MLN9708; MLN-9708; MLN 9708), the citrate salt and orally bioavailable prodrug of Ixazomib (MMLN2238; MMLN-2238), is a selective inhibitor of 20S proteasome (IC50 = 3.4 nM) with potential anticancer activity. It is being studies in a Phase II trial to treat multiple myeloma, amyloidosis and lymphoma in sorts of countries. Ixazomib citrate is a boron-containing compound that has to be hydrolyzed to MLN2238 (ixazomib) which is pharmacologically active. Compared with bortezomib, MLN9708 has improved pharmacokinetics, pharmacodynamics, and antitumor activity in preclinical studies.

纯度：≥98%

CAS：1239908-20-3